Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DSGN vs TERN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TERN Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–0 Matrix Metrics)

TERN Overall Winner 6-Pillar Tally: DSGN 1 – 3 TERN (2 Tie) Matrix Metrics: DSGN 0 – 5 TERN

As of Nov 16, 2026, Terns Pharmaceuticals, Inc. (TERN) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). DSGN carries a Unified Composite Score of 49.9/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin), whereas TERN carries 51.9/100 (HOLD) at $52.95 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile TERN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 74.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DSGN vs TERN
DSGN NASDAQ
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-5.06% 1D
Market Cap $677.5M
TTM Revenue $33,000
Forward P/E N/M
Beta / 30D Vol 1.32β · 61% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 63.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.7%), weak momentum, RSI 41
RSI-14: 41.4 · SMA20: $10.53 · SMA50: $11.59
TERN NASDAQ Head-to-Head Winner
Terns Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$52.95
+0.04% 1D
Market Cap $6.1B
TTM Revenue $1.0M
Forward P/E N/M
Beta / 30D Vol 0.07β · 2% Vol
Unified Composite Score
51.9 / 100 HOLD
Tech 40.0 Fund 42.0 Flow 60.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (14.7% over 20 days), RSI 75
RSI-14: 74.7 · SMA20: $52.78 · SMA50: $49.21

6-Pillar Scorecard Institutional Category Breakdown (DSGN 1 – 3 TERN)

Columns: Metric · DSGN · TERN
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale TERN
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $33,000 $1.0M
Market Cap $677.5M $6.1B
3. Profitability & Quality TERN
Gross Margin N/A 100.0%
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -36.9% -14.2%
4. Balance Sheet & Cash Flow DSGN
Cash Generation (TTM) -$59M -$110M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $13M Net Cash $8.96 Book/Sh · -14.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TERN
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 92.0% (13th %ile) 0.6% (<1st %ile)
Put/Call OI Skew N/A 0.21x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DSGN (0) vs TERN (5)
Institutional Metric DSGN TERN Criterion Row Edge
Market Capitalization
Scale
$677.5M $6.1B Larger Scale TERN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-36.9% -14.2% Higher ROE TERN
52-Week Range Position
Momentum
30% ($7–$17) 100% ($3–$53) Stronger Trend TERN
Beta / 30D Volatility
Risk Regime
1.32β · 61% Vol 0.07β · 2% Vol Lower Realized Risk TERN
Unified Institutional Score
Composite Signal
49.9 / 100 (HOLD) 51.9 / 100 (HOLD) Higher Composite TERN
Trailing 12M Revenue (USD)
Operating Scale
$33,000 $1.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$59M ($13M Net Cash) -$110M EBITDA ($8.96 Book/Sh · -14.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DSGN +16.84 pp
DSGN: +17.28% · TERN: +0.44%
3M Horizon TERN +17.3 pp
DSGN: +26.51% · TERN: +43.81%
6M Horizon TERN +68.89 pp
DSGN: +86.54% · TERN: +155.43%
1Y Horizon TERN +68.89 pp
DSGN: +86.54% · TERN: +155.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DSGN vs TERN. Trailing 12-month operating profitability (DSGN 0.0% vs TERN 0.0%) and valuation multiples (DSGN N/M vs TERN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DSGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$33,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-36.9% · N/M
TERN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.0M
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-14.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DSGN BREAKDOWN
139d in phase · OBV NEUTRAL
Current IV 92.0%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DSGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TERN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.6%
IV Percentile <1st %ile
Put/Call OI Skew 0.21x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TERN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DSGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TERN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DSGN vs TERN Key Questions & Quantitative Answers

As of Nov 16, 2026, Terns Pharmaceuticals, Inc. (TERN) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). DSGN carries a Unified Composite Score of 49.9/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin), whereas TERN carries 51.9/100 (HOLD) at $52.95 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile TERN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 74.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TERN leads the Growth & Scale pillar: DSGN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with TERN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (100.0% gross margin, 0.0% operating margin). On trailing 12-month operating scale, DSGN generates $33,000 in USD-normalized revenue versus $1.0M for TERN. In operating R&D and SG&A reinvestment, DSGN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TERN.

DSGN and TERN trade at balanced relative valuation multiples. DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TERN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DSGN (-36.9% ROE) versus TERN (-14.2% ROE) capital efficiency.

In options market volatility and institutional positioning, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk). By comparison, TERN carries 0.6% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.21x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.07β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.